Orforglipron is a new oral GLP-1 drug that outperforms oral semaglutide in blood sugar control and weight loss while offering easier manufacturing and storage, though it may cause more side effects.
A once-daily pill now in late-stage testing could push weight loss treatment into a new era. The drug, called orforglipron, is showing stronger results than current oral options for both lowering blood sugar and reducing body weight, raising the possibility of a simpler alternative to injections.
Just a few years ago, medications like semaglutide, sold as Wegovy and Ozempic, transformed obesity and diabetes care.
This medication belongs to a class called glucagon-like peptide-1 (GLP-1) drugs. These treatments mimic a natural hormone released after eating that signals fullness, slows digestion, and triggers insulin release. By copying this process, GLP-1 drugs have proven highly effective for managing type 2 diabetes and supporting weight loss.
Limitations of Injectable GLP-1 Treatments
Despite its success, semaglutide has drawbacks. It must be injected into areas such as the abdomen, thigh, or upper arm, which can be a barrier for people who dislike needles or prefer not to self-inject.
There are also logistical challenges. Injectable GLP-1 drugs require refrigeration throughout storage and transport, which complicates access in low- and middle-income countries.
These limitations have led researchers to explore oral alternatives.
Challenges With Current Oral Semaglutide
Based on current research, it appears that oral semaglutide is very effective. However, it must be taken on an empty stomach—and users must wait 30 minutes before eating or drinking.
Alongside being expensive to produce, it also has poor bioavailability compared with injectable semaglutide. This means only about 1% of the ingested drug is absorbed and able to exert its effects.
But a recent phase 3 clinical trial has shown that a new type of oral weight-loss pill may have overcome these issues—proving to be more effective than the current oral semaglutide products on the market.
Clinical Trial Results and Blood Sugar Control
The recent 52-week phase 3 trial involved 1,698 adults with type 2 diabetes across six countries. It set out to compare current oral semaglutide products against orforglipron, which is also taken as a daily tablet.
The primary measure researchers were looking for was a reduction in HbA1c. This blood test reflecting average blood sugar levels over three months is the standard indicator of diabetes control. Diabetes is present if HbA1c is 6.5% or more.
From a baseline average HbA1c of 8.3%, it was found that after 52 weeks, orforglipron was able to reduce this value by an average of 1.71–1.91%. In comparison, oral semaglutide only reduced HbA1c by 1.47%.
Superior Weight Loss but Tolerability Concerns
Not only did orforglipron meet the trial’s goals of proving it was as effective as oral semaglutide, but it also proved it was superior for lowering blood sugar. The participants who took orforglipron also lost more weight—an average of 6.1 kg to 8.2 kg, compared with 5.3 kg in those taking semaglutide.
However, a key issue highlighted by the trial was one of tolerability.
GLP-1 drugs can cause gastrointestinal side-effects such as nausea, vomiting, diarrhea, and constipation. In this latest trial, around 59% of participants on orforglipron reported such symptoms, compared with 37–45% on semaglutide.
Side Effects and Treatment Discontinuation
The reason for this difference may be the more prominent, daily peak drug concentrations with orforglipron. The consequence was that around 10% of orforglipron participants discontinued treatment due to adverse effects. Just 4-5% of those taking semaglutide discontinued treatment.
No head-to-head trials have been done of injectable GLP-1 versus orforglipron. However, the weight loss seen in this study of people with type 2 diabetes is broadly comparable with that previously observed with injectable GLP-1.
The trial’s results show that orforglipron, which was developed by Eli Lilly, can be considered one of semaglutide’s most credible challengers.
Small-Molecule Innovation and Manufacturing Advantages
Another remarkable thing about orforglipron is that it belongs to a new category of drugs called small-molecule drugs. This means it’s a synthetic chemical compound small enough to be absorbed directly through the gut wall. There, it’s able to act on GLP-1 receptors, even though it isn’t of a similar structure to a GLP-1 hormone.
Oral semaglutide, on the other hand, is a peptide drug. This means the structure of its amino acids (one of the building blocks of protein) closely resembles that of the natural GLP-1 hormone.
As a small-molecule drug, orforglipron is cheaper and simpler to manufacture than peptide-based drugs such as semaglutide.
Market Outlook and Future Research
And as with oral semaglutide, it requires no refrigeration. This gives it a logistical advantage over injectable GLP-1 formulations—a potentially important consideration for expanding access in low- and middle-income countries, where cold chain infrastructure is unreliable.
It remains to be seen, however, how orforglipron will perform against oral semaglutide in the broader market.
Although this latest trial has shown it is superior for controlling blood sugar and aiding weight loss, its higher rate of side effects and treatment discontinuation may temper enthusiasm. In a crowded and competitive market, long-term adherence—shaped as much by tolerability as by efficacy—is probably a critical differentiator.
Orforglipron is still undergoing trials in patients with obesity but without diabetes.
Adapted from an article originally published in The Conversation.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
1 Comment
The more the merrier.
Just make it over the counter & Humanity will be forever thankful